SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Dale J. Lange, M.D.
Hospital for Special Surgery/Weill Cornell Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Universitäts- Und Rehabilitationskliniken Ulm
Ulm, Germany
- Milano Neurological Institute
Milan, Italy
- Umea University
Umeå, Sweden
- Weill Cornell Medical Center/new York Presbyterian Hospital
New York, New York, United States
- Methodist Neurological Institute
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2009
- Primary completion
- 31 Dec 2014
- Completion
- 31 May 2016
- Last update posted
- 19 Jun 2017
- Registered enrollment
- 32
- Registry id
- NCT01083667
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.